Agendia’s BluePrint Included in German Oncology Group Guidelines

Agendia’s BluePrint Included in German Oncology Group Guidelines

By Karen Roman Agendia, Inc.’s BluePrint was recently included in the latest version of German Gynecological Oncology Group (AGO) guidelines for chemotherapy decision making. AGO is comprised of gynecological oncologists specialized in breast cancer and interdisciplinary members focused on pathology,...

Gameto Reports Clinical Progress in Women’s IVF Initiative

Gameto Reports Clinical Progress in Women’s IVF Initiative

By Daniella Parra Gameto, a female-led biotechnology firm, said it received tentative FDA approval to move to Phase 3 trials for Fertilo, a pivotal step towards Biologic License Application approval, the company said. The primary efficacy endpoint will assess pregnancy...

Acumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment

Acumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company, announced it signed an agreement with global pharmaceutical and biotech partner Lonza. The collaboration includes the manufacturing of sabirnetug (ACU193), an antibody for the treatment of Alzheimer’s disease...

Gameto Study Shows Improved Fertility Treatment Experience

Gameto Study Shows Improved Fertility Treatment Experience

By Daniella Parra Gameto, a biotech firm focused on women’s healthcare, shared a study examining the impact of minimal controlled ovarian stimulation on egg retrieval experiences. The analysis involved 110 patients with minimal stimulation cycles followed by OSC-IVM, 48 patients...

REGENXBIO Sees Positive Results For Macular Degeneration Therapy

REGENXBIO Sees Positive Results For Macular Degeneration Therapy

By Karen Roman REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, said its subretinal treatment of age-related macular degeneration showed improved vision in patients. Two years of data were published in The Lancet regarding the ongoing trials of ABBV-RGX-314, its...

Agendia Reports Findings for Breast Cancer Treatment

Agendia Reports Findings for Breast Cancer Treatment

By Karen Roman Agendia, Inc., a biotechnology company that provides molecular diagnostics and cancer treatment, said it can predict response and nonresponse to common neoadjuvant immunotherapy for patients with triple negative breast cancer. Agendia holds an FDA Investigational Device Exempt...

Conduit Pharmaceuticals Adds Key Leadership Positions

Conduit Pharmaceuticals Adds Key Leadership Positions

By Daniella Parra Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced the appointment of Dr. Joanne Holland as Chief Scientific Officer and Dr. Jeff Lindeman as a Consultant on intellectual property strategies. The company said Dr. Holland brings over 20 years of...

Conduit Pharmaceuticals Opens New Laboratory in UK

Conduit Pharmaceuticals Opens New Laboratory in UK

By Karen Roman Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, reported it has opened a new cutting-edge laboratory space in Cambridge, U.K. This new facility sits within a space of 150 acres and 2 million square feet...

Promontory Therapeutics Enrolls 109 Patients in Prostate Cancer Study

Promontory Therapeutics Enrolls 109 Patients in Prostate Cancer Study

By Daniella Parra Promontory Therapeutics Inc. completed enrollment of 109 late-stage metastatic castration-resistant prostate cancer patients for its Phase 2 trial of PT-112, which assesses its efficacy in patients who have undergone prior treatments, the company said. PT-112 is a...

Input your search keywords and press Enter.